Academic Journals Database
Disseminating quality controlled scientific knowledge

NQO1*2 [NAD(P)H: quinone oxidoreductase 1] polymorphism and its influence on acute leukemia risk

Author(s): NR. Dunna

Journal: Biology and Medicine
ISSN 0974-8369

Volume: 3;
Issue: 3;
Start page: 19;
Date: 2011;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: NQO1*2 | AML | ALL | polymorphism | DFS

NAD (P) H: quinone oxidoreductase 1 (NQO1) is an enzyme that protects cells against mutagenicity from freeradicals and toxic oxygen metabolites. The gene coding for NQO1 has polymorphism at nucleotide position 609(C-T)of the human cDNA. Heterozygous individuals (C/T) have intermediate activity and homozygotes for the variant allele(T/T) are deficient in NQO1 activity. In previous studies, genotypes conferring lower NQO1 activity have beenassociated with an increased risk of acute leukemia. The present study includes 297 acute leukemia casescomprising of 151 acute lymphocytic leukemia (ALL), 146 acute myeloid leukemia (AML) and 220 control samples foranalysis of NQO1*2 polymorphism using PCR-RFLP method. The NQO1*2 polymorphism was significantlyassociated with acute leukemia development (χ2- 31.614; df-2, p - < 0.000) with respect to clinical variables. MeanWBC, Blast %, LDH levels were increased in both ALL and AML cases with TT genotype. 50% of AML cases failed toachieve complete remission towards therapy. There was significant reduction in mean DFS (Disease Free Survival) inboth ALL and AML cases with TT genotype (21.18m, 8.31m). Our results suggest that TT genotype might beconsidered as a risk genotype for development of acute leukemia and is associated with poor prognostic markers.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?